Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis

  • Shu’an Wen
  • Wei Jing
  • Tingting Zhang
  • Zhaojing Zong
  • Yi Xue
  • Yuanyuan Shang
  • Fen Wang
  • Hairong HuangEmail author
  • Naihui ChuEmail author
  • Yu PangEmail author
Original Article


Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063 mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.


Mycobacterium tuberculosis Delamanid Pretomanid Susceptibility Minimum inhibitory concentration 



We thank the staff from the National Clinical Laboratory on Tuberculosis for their technical assistance.

Author contributions

SW, WJ, NC, YP, and HH designed this study. SW, WJ, TZ, ZZ, and YX performed the experiments. SW, WJ, YS, FW, and YP interpreted the data. SW, TZ, NC, YP, and HH wrote the manuscript. All authors approved the final version of the paper.

Funding information

This study was supported by the Beijing Talents Foundation (2017000021223ZK39), the Beijing Municipal Administration of Hospitals’ Youth Programme (QML20171601), the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20151501 and DFL20181602), and the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201809).


  1. 1.
    Denny WA, Palmer BD (2010) The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future Med Chem 2:1295–1304CrossRefGoogle Scholar
  2. 2.
    Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P (2015) Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:5316–5323CrossRefGoogle Scholar
  3. 3.
    Lee SFK, Laughon BE, Mchugh TD, Lipman M (2019) New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm MedGoogle Scholar
  4. 4.
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J (2018) Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis (Edinb) 111:20–30CrossRefGoogle Scholar
  5. 5.
    Manjunatha U, Boshoff HI, Barry CE (2009) The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2:215–218CrossRefGoogle Scholar
  6. 6.
    Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H (2017) In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 61Google Scholar
  7. 7.
    Shi J, Lu J, Wen S, Zong Z, Huo F, Luo J, Liang Q, Li Y, Huang H, Pang Y (2018) In vitro activity of PBTZ169 against multiple Mycobacterium species. Antimicrob Agents Chemother 62Google Scholar
  8. 8.
    Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, Shashkina E, Kreiswirth BN, Liu Y, Matsumoto M, Geiter L (2016) MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 60:3316–3322CrossRefGoogle Scholar
  9. 9.
    Stover CK, Warrener P, Vandevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, Mcmurray DN, Kreiswirth BN, Barry CE, Baker WR (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962–966CrossRefGoogle Scholar
  10. 10.
    Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG (2015) In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:136–144CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor InstituteCapital Medical UniversityBeijingChina
  2. 2.Department of Tuberculosis, Beijing Chest Hospital affiliated to Capital Medical UniversityBeijingTuberculosis and Thoracic Tumor Research InstituteBeijingChina

Personalised recommendations